physIQ, which uses wearable biosensor data to generate personalized, clinically valid, actionable insights announced a strategic collaboration with InCarda Therapeutics, Inc., and a privately-held, clinical-stage biopharmaceutical company developed inhaled therapies for cardiovascular diseases. In patients with atrial fibrillation, this collaboration is intended to speed up the Phase III study.
Abbott reported positive results from the PERSISTEND study of its TactiCath Contact Force Ablation Catheter, Sensor Enabled, in May 2022. (TactiCath SE) for persistent atrial fibrillation (AFib), the most common arrhythmia
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 4857
Published Date: Apr 28, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing technological advancements, new product launches, rise in people with atrial fibrillation conditions are the major factors driving the market growth.
The market size of atrial fibrillation surgery is anticipated to attain a CAGR of ~17.50% over the forecast period, i.e., 2023-2035.
High cost of ablation catheters, and lack of skilled professionals are estimated to be the growth hindering factors for the market expansion.
The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
The major players in the market are AtriCure, Inc., Biosense Webster, Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, CardioFocus, Inc., Endoscopic Technologies, Inc., Sanofi Aventis, Johnson and Johnson Ltd., Abbott Laboratories.
The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by procedure, end user, and region.
The catheter ablation segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.